The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Dose-related patterns of glucocorticoid-induced side effects
Abstract
Objective To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. Methods Data from 1066 patients were analysed. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing glucocorticoid treatment for more than 6 months and current doses of less than 5, 5-7.5 and over 7.5 mg/day prednisone equivalent were compared with a group without any glucocorticoid treatment for at least 12 months. Results The frequency of self-reported health problems was lowest in the group without glucocorticoid exposition and increased with dosage. Two distinct dose-related patterns of adverse events were observed. A "linear" rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath and sleep disturbance. A "threshold pattern" describing an elevated frequency of events beyond a certain threshold value was observed at dosages of over 7.5 mg/day for glaucoma, depression/listlessness and increase in blood pressure. Dosages of 5 mg/day or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/day). Conclusion The associations found are in agreement with biological mechanisms and clinical observations. As there is a paucity of real-life data on adverse effects of glucocorticoids prescribed to unselected groups of patients, these data may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dose-related pattern was found for clinical features such as cushingoid phenotype, skin thinning, ecchymosis, and sleep disturbances.”
From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [35]
In the citing paper
“Although other adverse effects manifested above a certain threshold of daily glucocorticoid dosage (eg, epistaxis and weight gain with daily prednisone equivalent dose of > 5.0-7.5 mg), whereas depression and high blood pressure were especially prevalent with > 7.5 mg/d (35).”
From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [35]
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,742
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Polymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani, C., Cantini, F., Boiardi, L., & Hunder, G. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011913 · Cited by 1,360
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 833
The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis
Kirwan, J. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507203330302 · Cited by 817
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Buttgereit, F., Da Silva, J. A. P., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., Kirwan, J., Köhler, L., van Riel, P., Vischer, T., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.718 · Cited by 544
Self-citationSaag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B. M., Kohler, J. A., & Fürst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 529
Self-citationvan Everdingen, A. A., Jacobs, J. W. G., van Reesema, D. R. S., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 488
Hoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E., Cutolo, M., da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 416
Self-citationGlucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. R. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 359
Self-citationWassenberg, S., Rau, R., Steinfeld, P., Zeidler, H. K., & Low‐Dose Prednisolone Therapy Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21421 · Cited by 308
Optimised glucocorticoid therapy: the sharpening of an old spear
Buttgereit, F., Burmester, G. R., & Lipworth, B. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17989-6 · Cited by 221
Self-citationHickling, P., Jacoby, R. K., & Kirwan, J. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.9.930 · Cited by 201
Mechanisms of glucocorticoid–induced hypertension
Whitworth, J. A. (1987) · Kidney International · doi:10.1038/ki.1987.131 · Cited by 173
Capell, H. A., Madhok, R., Hunter, J. A., Porter, D., Morrison, E., Larkin, J., Thomson, E. A., Hampson, R., & Poon, F. W. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.014050 · Cited by 158
Lautenschläger, J., Mau, W., Kohlmann, T., Raspe, H. H., Struve, F., Brückle, W., & Zeidler, H. K. (1997) · Zeitschrift für Rheumatologie · doi:10.1007/s003930050030 · Cited by 148
Zink, A., Listing, J., Klindworth, C., & Zeidler, H. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.3.199 · Cited by 131
Self-citationThe efficacy and safety of low-dose corticosteroids for rheumatoid arthritis
Caldwell, J. R., & Fürst, D. E. (1991) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(91)90051-z · Cited by 115
Does Long-Term Low-Dose Corticosteroid Therapy Cause Hypertension?
Jackson, S. H. D., Beevers, D. G., & Myers, K. (1981) · Clinical Science · doi:10.1042/cs061381s · Cited by 63
Current use of glucocorticoids in patients with rheumatoid arthritis in Germany
Thiele, K., Buttgereit, F., Huscher, D., & Zink, A. (2005) · Arthritis Care & Research · doi:10.1002/art.21467 · Cited by 61
Self-citationZink, A., Listing, J., Niewerth, M., & Zeidler, H. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.3.207 · Cited by 57
Self-citationfor the LDPT-Study Group, Rau, R., Wassenberg, S., & Zeidler, H. K. (2000) · Zeitschrift für Rheumatologie · doi:10.1007/s003930070026 · Cited by 57
Adverse effects of corticosteroids.
Bialas, M. C., & Routledge, P. A. (1998) · PubMed · Cited by 45
Developments in Glucocorticoid Therapy
Bijlsma, J. W. J., Saag, K. G., Buttgereit, F., & da Silva, J. A. P. (2005) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.10.003 · Cited by 40
Self-citationAdverse effects of corticosteroids: II. systemic
Davis, G. F. (1986) · Clinics in Dermatology · doi:10.1016/0738-081x(86)90020-9 · Cited by 33
Principles of Corticosteroid Therapy
Lin, A. N., & Paget, S. A. (1998) · Cited by 19
Longterm studies in rheumatoid arthritis--the German experience.
Zink, A., & Huscher, D. (2004) · PubMed · Cited by 13
Self-citationHatz, H. J., & Helmke, K. (1992) · PubMed · Cited by 13
Buttgereit, F., Seibel, M. J., & Bijlsma, J. W. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10087-9 · Cited by 9
Self-citationRisks of glucocorticoid treatment—are they related to treatment duration and dosage?
Kavanaugh, A. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0343 · Cited by 2
Flagged first, then by citations
Research works printed but not linked: 1
- Lautenschlaeger, 1997, [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire], Z Rheumatol, 56, 144
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., Clair, E. W. S., Arayssi, T., Carandang, K. M., Deane, K. D., Genovese, M. C., Huston, K. K., Kerr, G. S., et al. (2021) · Arthritis Care & Research · doi:10.1002/acr.24596 · Cited by 1,355
“…frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases (62– 65).”
BackgroundKumar, S., & Kelly, A. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.017 · Cited by 1,421
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P. K., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,214
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
Metadata
- Authors
- Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F.
- Affiliations
- German Rheumatism Research Centre (DE)
- Jena University Hospital (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Huscher, D
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 68
- Issue
- 7
- Pages
- 1119-1124
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2167459187
- Cited by
- 604
- References
- 35
- Citations by year
- 2026: 43 · 2025: 55 · 2024: 67 · 2023: 55 · 2022: 47 · 2021: 41 · 2020: 49 · 2019: 38 · 2018: 27 · 2017: 28 · 2016: 32 · 2015: 21 · 2014: 26 · 2013: 28 · 2012: 19
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- glucocorticoid adverse effects, dose-response relationship, rheumatoid arthritis, prednisone-equivalent dose, glaucoma, cataract, depression, hypertension, weight gain, bruising, lower limb edema, fungal infection, sleep disorders, risk-benefit ratio, threshold dose
- MeSH terms
- Arthritis, Rheumatoid, Data Collection, Dose-Response Relationship, Drug, Female, Glucocorticoids, Humans, Male, Middle Aged, Risk Factors, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
